Overview

• Bristol Myers will pay BioNTech $1.5 billion upfront plus up to $2 billion in non-contingent anniversary payments through 2028 and BioNTech may earn up to $7.6 billion in development and commercial milestones
• The companies will equally share global development costs, manufacturing expenses and any future profits or losses from BNT327
• BNT327 is a next-generation bispecific antibody engineered to target PD-L1 and VEGF-A proteins and boost patients’ immune response against solid tumors
• More than 20 clinical trials are ongoing or planned for lung, breast and other cancers, with over 1,000 patients treated in initial studies
• BioNTech’s $800 million acquisition of China’s Biotheus in November 2024 reinforced its oncology research platform ahead of this partnership